Seattle Genetics, Inc. (NASDAQ:SGEN)

CAPS Rating: 3 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Recs

0
Player Avatar TMFBiologyFool (98.28) Submitted: 9/13/2010 3:53:57 PM : Outperform Start Price: $12.21 SGEN Score: +51.28

Nice pipeline of drugs.

Report this Post Reply

Featured Broker Partners


Advertisement